Profound Medical Earns INOVAIT Award, Accelerates TULSA Expansion
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Profound Medical ( (TSE:PRN) ) is now available.
On February 12, 2026, Profound Medical Corp. announced that INOVAIT, Canada’s national network for image-guided therapy and AI commercialization, had honored the company with the 2025–2026 Mount Logan Award for its TULSA Procedure for prostate disease. The recognition follows a year in which Profound treated its 4,000th TULSA patient, gained new U.S. Medicare reimbursement codes and advanced strategic partnerships to broaden global access.
The award underscores the clinical and commercial momentum of Profound’s iMRI-guided TULSA-PRO system, which offers a non-incision, non-radiation option for prostate cancer and benign prostatic hyperplasia with reduced side effects and no hospital stay. Management highlighted plans to accelerate commercialization by expanding direct sales in North America, rebuilding its Canadian presence after regaining local distribution rights and leveraging select distributors internationally, with Sunnybrook Health Sciences Centre in Toronto serving as a key Canadian reference site.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company focused on interventional MRI procedures, developing and marketing minimally invasive, image-guided therapies. Its lead technology, TULSA-PRO, enables the incision- and radiation-free TULSA Procedure for a broad spectrum of prostate diseases, while Sonalleve targets indications such as uterine fibroids and osteoid osteoma across global regulated markets.
The company’s platforms combine real-time MRI, AI-enhanced planning and robotically controlled ultrasound to ablate targeted tissue with high precision, aiming to preserve quality-of-life outcomes and shorten recovery times. TULSA-PRO is cleared or approved in key jurisdictions including the U.S., Europe and Canada, and Sonalleve holds approvals in Europe, China and the U.S., positioning Profound within the growing market for non-invasive, image-guided cancer and benign disease therapies.
Average Trading Volume: 20,855
Technical Sentiment Signal: Sell
Current Market Cap: C$312.8M
See more insights into PRN stock on TipRanks’ Stock Analysis page.
